©
2004 - 2009 |
|||||||||||||||
|
|
- Effect of granulocyte macrophage-colony stimulating factor (GM-CSF, sargramostim) administration on serum S100B and its subtypes in melanoma patients. B. De Gast, C. Korse, R. Weber, S. Trautveter, J. Bonfrer, L. Spitler
- Nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable stage III and IV melanoma. P. Boasberg, S. Cruickshank, O. Hamid, S. O'Day, R. Weber, L. Spitler; The Angeles Clinic and Research Institute, Santa Monica, CA; Scott Cruickshank and Associates, Santa Barbara, CA; The Angeles Clinic and Research Institute, Santa Monica , CA; N. Ca. Melanoma Center at St Mary's Medical Center, San Francisco, CA
- Immunological effects and clinical outcomes in patients with high-risk melanoma given adjuvant therapy with granulocyte-macrophage colony stimulating factor (GM-CSF, sargramostim). L. E. Spitler, R. W. Weber, S. Cruickshank, T. L. Whiteside; Northern California Melanoma Center, San Francisco, CA; Scott Cruickshank & Associates, Santa Barbara, CA; University of Pittsburgh, Pittsburgh, PA
- Adjuvant
Therapy of Stage III and IV Malignant Melanoma Using Granulocyte-Macrophage
Colony-Stimulating Factor (PDF)
- Low-Dose
Outpatient Chemobiotherapy With Temozolomide, Granulocyte-Macrophage
Colony Stimulating Factor, Interferon-aplha2b, and Recombinant Interleukin-2
for the Treatment of Metastatic Melanoma (PDF)
- Noninterferon-based
Adjuvant Therapy for High Risk Melanoma (PDF)
- Value of Alpha Interferon in Adjuvant Therapy for Melanoma: The Case Against (PDF)
